- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05068011
Differentieel doel Gemultiplexte ruggenmergstimulatie (DETECT)
Differentieel doel gemultiplexte ruggenmergstimulatie: een multicenter cohortonderzoek
Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
-
Antwerp, België
- ZNA
-
Bruges, België
- AZ Sint-Jan Brugge-Oostende
-
Bruges, België
- AZ Sint-Lucas Brugge
-
Hasselt, België
- Jessa Ziekenhuis
-
Kortrijk, België
- AZ Groeninge
-
Leuven, België
- UZ Leuven
-
Lier, België
- Heilig Hart Ziekenhuis Lier
-
Liège, België
- Centre Hospitalier Régional (CHR) de la Citadelle
-
Mechelen, België
- AZ Sint-Maarten
-
Roeselare, België
- AZ Delta
-
Sint-Niklaas, België
- Vitaz
-
Turnhout, België
- AZ Turnhout
-
Wilrijk, België
- GZA
-
-
Brussels Capital
-
Jette, Brussels Capital, België, 1090
- Universitair Ziekenhuis Brussel
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients with chronic back and leg pain due to Failed Back Surgery Syndrome (FBSS)/Persistent Spinal Pain Syndrome type 2 (PSPS-T2), who will receive treatment with differential target multiplexed (DTM) SCS.
Beschrijving
Inclusion Criteria:
- Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
- Age > 18 years
- Patient has been informed of the study procedures and has given written informed consent
- Patient willing to comply with study protocol including attending the study visits
Exclusion Criteria:
- Expected inability of the patient to receive or properly operate the spinal cord stimulation system
- History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
- Active malignancy
- Addiction to drugs, alcohol (>5 units per day) and/or medication
- Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
- Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
- Life expectancy < 1 year
- Local infection or any other skin disorder at site of incision
- Pregnancy
- Other implanted active medical device
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Spinal cord stimulation
Patients will receive differential target multiplexed spinal cord stimulation |
differential target multiplexed stimulation |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Overall pain intensity with Visual Analogue Scale (VAS)
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Rugpijnintensiteit met Visual Analogue Scale (VAS)
Tijdsspanne: De verandering tussen de nulmeting en de evaluatie 1 maand na DTM-stimulatie, 6 maanden en 12 maanden
|
De verandering tussen de nulmeting en de evaluatie 1 maand na DTM-stimulatie, 6 maanden en 12 maanden
|
|
|
Pijnintensiteit in het been met Visual Analogue Scale (VAS)
Tijdsspanne: De verandering tussen de nulmeting en de evaluatie 1 maand na DTM-stimulatie, 6 maanden en 12 maanden
|
De verandering tussen de nulmeting en de evaluatie 1 maand na DTM-stimulatie, 6 maanden en 12 maanden
|
|
|
Klinische holistische responderstatus
Tijdsspanne: De verandering tussen de nulmeting en de evaluatie 1 maand na DTM-stimulatie, 6 maanden en 12 maanden
|
De verandering tussen de nulmeting en de evaluatie 1 maand na DTM-stimulatie, 6 maanden en 12 maanden
|
|
|
Percentage succesvolle DTM-proeven.
Tijdsspanne: Geëvalueerd na definitieve SCS-implantatie
|
Geëvalueerd na definitieve SCS-implantatie
|
|
|
Batterij verbruik
Tijdsspanne: Registratie op 1 maand, 6 maanden en 12 maanden DTM SCS
|
Registratie op 1 maand, 6 maanden en 12 maanden DTM SCS
|
|
|
Prevalentie van technische problemen met betrekking tot DTM SCS-programmering
Tijdsspanne: Gedurende de hele studieperiode
|
Gedurende de hele studieperiode
|
|
|
DTM SCS-stimulatieparameters
Tijdsspanne: Registratie op 1 maand, 6 maanden en 12 maanden DTM SCS
|
Registratie op 1 maand, 6 maanden en 12 maanden DTM SCS
|
|
|
Pain medication use
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Open question regarding the dosage, frequency and type of pain medication |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Functional disability
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The functional disabilities will be assessed with the Oswestry Disability Index (ODI) |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Health related quality of life
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Health related quality of life, evaluated with the EuroQol with five dimensions and 5 levels |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Patient global impression of change
Tijdsspanne: Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
Patients will be asked to quantify the impression of change after treatment using the Patient Global Impression of Change scale (PGIC). |
Evaluated at 1 month, 6 months and 12 months of DTM SCS.
|
|
Patients' individual competencies for self-management
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Patient activation measure-13 (PAM) is a 13-item instrument which assesses self-reported behaviour, knowledge, and confidence for self-management of one's health. |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Work status
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
Work status is evaluated with a self-designed questionnaire |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Pain catastrophizing
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Pain Catastrophizing Scale (PCS) will be used to measure the level of pain catastrophizing |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Symptoms of central sensitisation.
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The Central Sensitization Inventory is used to measure symptoms of central sensitisation |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Anxiety and Depression.
Tijdsspanne: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
The hospital Anxiety and Depression Scale (HADS) will measure symptoms of anxiety and depression |
The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months
|
|
Healthcare utilisation.
Tijdsspanne: The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
Postoperative healthcare expenditure will be investigated by self-reporting methods. |
The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS
|
|
Time spent in body postures
Tijdsspanne: The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
Based on the AdaptiveStim technology, the time spent in body postures can be recorded. |
The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months
|
|
(Serious) adverse events
Tijdsspanne: Throughout study period
|
Systematically recording all adverse events |
Throughout study period
|
|
Patient expectations concerning SCS
Tijdsspanne: Evaluated at baseline visit
|
Self-constructed open question to evaluate patient expectations about SCS |
Evaluated at baseline visit
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pijn
- Neurologische manifestaties
- Postoperatieve complicaties
- Pathologische processen
- Rugpijn
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Failed Back Surgery Syndroom
- Therapeutica
- Modaliteiten fysiotherapie
- Revalidatie
- Elektrische stimulatietherapie
- Stimulatie van ruggenmerg
Andere studie-ID-nummers
- DETECT
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .